Back to Agenda
Session 10: Advanced Therapies
Session Chair(s)
Robert L. Levin, MD
Lead Medical Officer for Pharmacovigilance Strategy
FDA, United States
Session Chair
Speaker(s)
James Wabby, MHS
AbbVie, United States
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
Precision Medicine, Pharmacovigilance, and Risk Management
Gerald L. Messerschmidt, MD, FACP
Precision Oncology, United States
Chief Medical Officer
Pharmacovigilance and Risk Management of Advanced Therapies
Dina Tresnan, DVM, PhD
Pfizer Inc, United States
SSRM Disease Area Cluster Lead - Oncology
Safety Considerations for Regenerative Medicine
Abla Creasey, PhD
California Institute of Regenerative Medicine, United States
Vice President Therapeutics Development
Have an account?